To evaluate the therapeutic effects and safety of Baduanjin in the treatment of heart failure.Methods:The database of CNKI, Chinese biomedical literature database, Wanfang database, VIP full text database, PubMed, Cochrane Library, web of science, and EMBASE were searched.The time range for document retrieval was from the establishment of database to February 28th, 2019.Risk of bias was assessed using the Cochrane manual for included RCT studies, and Meta-analysis was performed using Rev Man 5.3 software.Results:A total of 543 patients suffering heart failure were enrolled in 6 papers and 7 randomized controlled studies.Compared with the control group, the treatment group reduced MLHFQ[MD=10.88, 95%CI=(8.22, 13.54)]; 6 WMT distance improved[MD=107.81, 95%CI=(75.83, 139.78)]; LVEF improved[MD=3.62, 95%CI=(2.04, 5.19)]; BNP improved[MD=73.32, 95%CI=(45.12, 101.53)]; clinical efficacy[OR=4.00, 95%CI=(1.35, 11.83)], TCM syndrome scores[OR=4.57, 95%CI=(2.03, 10.31)].Conclusion:Baduanjin can improve the cardiac function of patients with heart failure and is used for stable rehabilitation treatment.